ANRO Valuation

Alto Neuroscience Inc

Add to Watchlist

Advanced Chart

12.170

-2.02(-14.235%)1D

ANRO Relative Valuation

ANRO's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, ANRO is overvalued; if below, it's undervalued.

Historical Valuation

Alto Neuroscience Inc (ANRO) is now in the Fair zone, suggesting that its current forward PS ratio of 14.19 is considered Fairly compared with the five-year average of -2.91. The fair price of Alto Neuroscience Inc (ANRO) is between to according to relative valuation methord.

Relative Value

Fair Zone

Current Price：14.19

Fair

-4.84

Trailing

Forward

-2.88

EV/EBITDA

Alto Neuroscience Inc. (ANRO) has a current EV/EBITDA of -2.88. The 5-year average EV/EBITDA is 0.18. The thresholds are as follows: Strongly Undervalued below -0.58, Undervalued between -0.58 and -0.20, Fairly Valued between 0.56 and -0.20, Overvalued between 0.56 and 0.94, and Strongly Overvalued above 0.94. The current Forward EV/EBITDA of -2.88 falls within the Strongly Undervalued range.

-3.16

EV/EBIT

Alto Neuroscience Inc. (ANRO) has a current EV/EBIT of -3.16. The 5-year average EV/EBIT is -1.13. The thresholds are as follows: Strongly Undervalued below -6.39, Undervalued between -6.39 and -3.76, Fairly Valued between 1.50 and -3.76, Overvalued between 1.50 and 4.14, and Strongly Overvalued above 4.14. The current Forward EV/EBIT of -3.16 falls within the Historic Trend Line -Fairly Valued range.

12.17

Alto Neuroscience Inc. (ANRO) has a current PS of 12.17. The 5-year average PS is 0.18. The thresholds are as follows: Strongly Undervalued below -2.93, Undervalued between -2.93 and -1.37, Fairly Valued between 1.74 and -1.37, Overvalued between 1.74 and 3.30, and Strongly Overvalued above 3.30. The current Forward PS of 12.17 falls within the Strongly Overvalued range.

-5.54

P/OCF

Alto Neuroscience Inc. (ANRO) has a current P/OCF of -5.54. The 5-year average P/OCF is -3.30. The thresholds are as follows: Strongly Undervalued below -7.89, Undervalued between -7.89 and -5.59, Fairly Valued between -1.00 and -5.59, Overvalued between -1.00 and 1.29, and Strongly Overvalued above 1.29. The current Forward P/OCF of -5.54 falls within the Historic Trend Line -Fairly Valued range.

-5.14

P/FCF

Alto Neuroscience Inc. (ANRO) has a current P/FCF of -5.14. The 5-year average P/FCF is -3.20. The thresholds are as follows: Strongly Undervalued below -7.73, Undervalued between -7.73 and -5.46, Fairly Valued between -0.93 and -5.46, Overvalued between -0.93 and 1.33, and Strongly Overvalued above 1.33. The current Forward P/FCF of -5.14 falls within the Historic Trend Line -Fairly Valued range.

Alto Neuroscience Inc (ANRO) has a current Price-to-Book (P/B) ratio of 3.11. Compared to its 3-year average P/B ratio of 0.95 , the current P/B ratio is approximately 226.88% higher. Relative to its 5-year average P/B ratio of 0.95, the current P/B ratio is about 226.88% higher. Alto Neuroscience Inc (ANRO) has a Forward Free Cash Flow (FCF) yield of approximately -14.74%. Compared to its 3-year average FCF yield of -37.69%, the current FCF yield is approximately -60.90% lower. Relative to its 5-year average FCF yield of -37.69% , the current FCF yield is about -60.90% lower.

2.67

P/B

Median3y

0.95

Median5y

0.95

-0.15

FCF Yield

Median3y

-37.69

Median5y

-37.69

Competitors Valuation Multiple

The average P/S ratio for ANRO's competitors is 6.62, providing a benchmark for relative valuation. Alto Neuroscience Inc Corp (ANRO) exhibits a P/S ratio of 12.17, which is 83.98% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

ANRO.N

Alto Neuroscience Inc

Design Therapeutics Inc

Galectin Therapeutics Inc

Performance Decomposition

Market capitalization of ANRO increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00%to the performance.

Overall, the performance of ANRO in the past 1 year is driven by Unknown.